AchillesLatest News

ACHILLES’ FOUNDERS MAP TRUNCAL AND BRANCHED MUTATIONS AND COPY NUMBER EVENTS TO PREDICT EARLY RELAPSE IN NON-SMALL CELL LUNG CANCER.

26/04/2017

Achilles Founders map truncal and branched mutations and copy number events to predict early relapse in non-small cell cancer lungs, opening...

Read More +

ACHILLES STARTS 2017 WITH MOVE TO STEVENAGE BIOSCIENCE CATALYST

03/01/2017

Achilles Therapeutics starts 2017 with move to Stevenage Bioscience Catalyst Immunotherapy company joins growing cell & gene therapy community on campusStevenage, UK,...

Read More +

ACHILLES LAUNCHES WITH FUNDS OF £13.2M TO DEVELOP IMMUNOTHERAPIES FOR CANCER

28/09/2016

ACHILLES THERAPEUTICS LAUNCHED WITH FUNDS OF £13.2 MILLION TO DEVELOP IMMUNOTHERAPIES FOR CANCER Wednesday 5 October, 2016 SYNCONA LLP and CANCER...

Read More +

Sign up foremail alerts

We'll keep you connected to the latest news about Achilles

By providing your name and email address, you consent to Achilles Therapeutics Limited using these details to send you emails relating to the latest news and updates about Achilles. You can withdraw your consent at any time by emailing dataprotection@achillestx.com, or clicking on the unsubscribe link at the end of any email you receive from us. For more information, including your rights relating to your personal data, please see our Privacy Policy